Bandim Health Project
Guinea-Bissau
- Country
- Guinea-Bissau
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.bandim.org
Clinical Trials
59
Active:0
Completed:34
Trial Phases
4 Phases
Phase 1:1
Phase 3:3
Phase 4:40
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (52 trials with phase data)• Click on a phase to view related trials
Phase 4
40 (76.9%)Not Applicable
8 (15.4%)Phase 3
3 (5.8%)Phase 1
1 (1.9%)BCG Revaccination With the Third Dose of Diphtheria-tetanus-pertussis Vaccine and Infant Mortality in Africa
Phase 4
- Conditions
- Infant MorbidityInfant MortalityNon-Specific Effects of VaccinesBCG
- Interventions
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Bandim Health Project
- Target Recruit Count
- 6000
- Registration Number
- NCT07005726
- Locations
- 🇬🇼
Bandim Health Project, Bissau, Guinea-Bissau
The Non-Specific Immunological Effects of Providing Oral Polio Vaccine to Seniors in Guinea-Bissau
Phase 4
- Conditions
- Vaccine Reaction
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Bandim Health Project
- Target Recruit Count
- 80
- Registration Number
- NCT06266754
- Locations
- 🇬🇼
Bandim Health Project, Apartado 861, Bissau, Guinea-Bissau
Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau
Phase 4
Recruiting
- Conditions
- BCG Vaccination ReactionDiabetes Mellitus
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Bandim Health Project
- Target Recruit Count
- 200
- Registration Number
- NCT05591339
- Locations
- 🇬🇼
Bandim Health Project, Bissau, Guinea-Bissau
Trial to Compare BCG-Bulgaria and BCG-Denmark
Phase 4
Recruiting
- Conditions
- Morbidity;NewbornMorbidity;InfantNon-specific Effects of VaccinesDeath; NeonatalDeath, Infant
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Bandim Health Project
- Target Recruit Count
- 15000
- Registration Number
- NCT05397678
- Locations
- 🇬🇼
Bandim Health Project, Bissau, Guinea-Bissau
Effectiveness and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for Treating Malaria
Phase 4
Completed
- Conditions
- EffectivenessMalaria
- Interventions
- Drug: Dihydroartemisinin-piperaquine 160 mg/20 mg Oral TabletDrug: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Bandim Health Project
- Target Recruit Count
- 474
- Registration Number
- NCT04897919
- Locations
- 🇬🇼
Bandim Health Centre, Bissau, Bissau Codex, Guinea-Bissau
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
No news found